Tissue repair research has some of the most measurable endpoints in peptide science — wound closure rates, tendon breaking strength, fibroblast proliferation, cytokine panels. That reproducibility is part of why this category has one of the deepest published literatures of any research-peptide class.
This guide organizes the leading recovery and repair research peptides by where each one acts in the repair cascade, so researchers can map compounds to the specific phase their protocol targets. For the full cross-category list, see our Best Research Peptides 2026 guide, and for combination protocols see Best Research Peptide Stacks 2026.
The Repair Cascade: A Research Framework
Tissue repair unfolds in three overlapping phases, and different compounds are studied at different points along that timeline:
- Phase 1 — Hemostasis and acute inflammation. Pro-inflammatory cytokines (IL-1β, IL-6, TNF-alpha) recruit immune cells to the injury site. Necessary, but damaging if it persists too long.
- Phase 2 — Proliferation. Fibroblasts and endothelial cells migrate to the site, growth factors (VEGF, PDGF, EGF) direct new tissue formation, and angiogenesis begins.
- Phase 3 — Remodeling. Newly deposited collagen is reorganized and cross-linked into mature matrix, a process that can continue for months.
BPC-157: The Most Published Repair Peptide
BPC-157 (Body Protection Compound 157) has one of the largest published research bases of any tissue-repair peptide, with work spanning gastric ulcer healing, tendon and ligament repair, bone healing, and peripheral nerve regeneration across several decades of preclinical literature.
The most consistent finding across that literature is upregulation of VEGF, PDGF, and EGF at injury sites — placing BPC-157's primary activity squarely in the proliferation phase. Researchers at the University of Zagreb have also proposed a nitric oxide (NO) signaling component to BPC-157's effects; several studies using NO-pathway inhibitors found that blocking NO production attenuated the compound's repair effects, which supports a causal rather than incidental role. BPC-157's VEGF-driven angiogenic activity is particularly relevant in tendon research, where poor native vascularization is normally the rate-limiting factor in repair.
See our BPC-157 mechanism of action, BPC-157 preclinical research, and BPC-157 in gut research pages for the full breakdown.
TB-500: Actin Regulation and Cell Migration
TB-500 is Ac-LKKTETQ, a synthetic heptapeptide corresponding to amino acids 17–23 of Thymosin Beta-4 — the region responsible for its actin-binding activity. Its studied mechanism centers on regulating G-actin (the soluble, monomeric form) and controlling how readily it polymerizes into F-actin, the structural form cells use to physically move.
Because cell migration into an injury site is a proliferation-phase requirement, TB-500's research role complements BPC-157's growth-factor signaling rather than duplicating it — BPC-157 tells the tissue what needs to happen, TB-500 supports the cellular machinery that carries it out. This complementary mechanism is why the two are frequently studied together. See our TB-500 mechanism of action and TB-500 in angiogenesis research pages.
The Wolverine Stack: BPC-157 + TB-500
The pre-combined BPC-157 + TB-500 Wolverine Stack is the most frequently referenced multi-peptide combination in tissue-repair research, precisely because the two compounds' mechanisms sit at different points in the same proliferation phase rather than competing for the same pathway. See BPC-157 + TB-500 combination research and BPC-157 vs. TB-500 for a side-by-side mechanism comparison.
KPV: Inflammatory Modulation Research
KPV, the C-terminal tripeptide of alpha-MSH, is studied for its effects on NF-κB pathway signaling — the transcription factor cascade that drives much of the acute inflammatory response. Because its research relevance sits in Phase 1 rather than Phase 2 or 3, KPV is frequently studied alongside BPC-157 and TB-500 to cover the earlier part of the repair timeline that neither of those compounds directly addresses. See our KPV mechanism of action and KPV research overview.
GHK-Cu: Extracellular Matrix Research
GHK-Cu, a copper-binding tripeptide, is studied for its role in matrix metalloproteinase modulation and collagen synthesis — activity that maps most directly to Phase 3, the remodeling phase where newly laid-down collagen gets reorganized into functional tissue. This makes GHK-Cu a common addition to repair stacks that already cover the earlier inflammatory and proliferative phases. See GHK-Cu in skin and collagen research and GHK-Cu mechanism of action.
The KLOW Stack combines GHK-Cu, BPC-157, TB-500, and KPV specifically to span all three repair phases in a single research protocol — see our KLOW Stack research overview for the complete four-compound rationale, or Best Research Peptide Stacks 2026 for how it compares to the two-compound Wolverine Stack.
Neural Recovery Research: Selank and Semax
Recovery research isn't limited to musculoskeletal and dermal tissue. Selank and Semax are both studied in neural-recovery contexts, with research interest in stress-response modulation and neurotrophic signaling (including BDNF expression) respectively. These compounds are typically studied independently of the musculoskeletal repair peptides above, reflecting the distinct receptor systems and tissue targets involved. See Selank mechanism of action and Semax mechanism of action.
Recovery & Repair Peptide Comparison
| Compound | Repair Phase | Primary Studied Mechanism |
|---|---|---|
| KPV | 1 — Acute inflammation | NF-κB pathway modulation |
| BPC-157 | 2 — Proliferation | VEGF/PDGF/EGF upregulation, NO signaling |
| TB-500 | 2 — Proliferation | G-actin regulation, cell migration |
| GHK-Cu | 3 — Remodeling | MMP modulation, collagen synthesis quality |
| Selank / Semax | Neural recovery (separate system) | Stress-response and neurotrophic signaling |
FAQ
Do these compounds need to be studied together to be useful? No — each has an independent research literature. Combination protocols (like Wolverine or KLOW) are studied specifically when a protocol needs coverage across multiple repair phases in the same model.
Which compound has the deepest published literature? BPC-157, by a wide margin — it's the most extensively published tissue-repair research peptide currently available.
All compounds referenced are offered strictly for in vitro and laboratory research use. Nothing in this guide constitutes a recommendation for human or veterinary administration.